Adenovirus-mediated p53 gene therapy in nasopharyngeal cancer

International Journal of Oncology

Volumn 11, Issue 2, 1997, Pages 221-226

  Zeng, Y I Xin ^a,b   Prabhu, Nita S ^a   Meng, Ray ^a   El Deiry, Wafik S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Adenovirus; Gene therapy; Nasopharyngeal cancer; p53

Indexed keywords

PROTEIN P53; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; CANCER RISK; GENE THERAPY; HUMAN; HUMAN CELL; NASOPHARYNX CANCER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0030787004     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.11.2.221     Document Type: Article

References (25)

1. Fandi A and Cvitkovic E: Biology and treatment of nasopharyngcal cancer. Curr Opin in Oncol 7: 255-263, 1995.
2. Velculescu VE and El-Deiry WS: Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 42: 858-868, 1996.
3. Sun Y, Hegameyer GH, Cheng YJ, Hildesheim A, Chen JY, Chen I-H, Cao Y, Yao K-T and Colburn NH: An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc Natl Acad Sci USA 89: 6516-6520, 1992.
4. Fries KL, Miller WE and Raab-Traub N: Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. J Virol 70: 8653-8659, 1996.
5. Theodorakis P, D'Sa-Eipper C, Subramanian T and Chinnadurai G: Unmasking of a proliferation-restraining activity of the anti-apoptosis protein EBV BHRF1. Oncogene 12: 1707-1713, 1996.
6. Szekely L, Selivanova G, Magnusson KP, Klein G and Wiman KG: EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc Natl Acad Sci USA 90: 5455-5459, 1993.
7. Okan I, Wang Y, Chen F, Hu LF, Imreh S, Klein G and Wiman KG: The EBV-encoded LMP1 protein inhibits p53-triggered apoptosis but not growth arrest. Oncogene 11: 1027-1031, 1995.
8. Allday MJ, Sinclair A, Parker G, Crawford DH and Farrell PJ: Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53. EMBO J 14: 1382-1391, 1995.
9. Cherney BW, Bhatia K and Tosato G: A role for deregulated c-myc expression in apoptosis of Epstein-Barr virus-immortalized B cells. Proc Natl Acad Sci USA 91: 12967-12971, 1994.
10. Porter MJ, Field JK, Leung SF, Lo D, Lee JC, Spandidos DA and van Hasselt CA: The detection of the c-myc and ras oncogenes in nasopharyngeal carcinoma by immunohistochemistry. Acta Oto-Laryngol 114: 105-109, 1994.
11. Lin CT, Chan WY, Chen W, Huang HM, Wu HC, Hsu MM, Chuang SM and Wang CC: Characterization of seven newly established nasopharyngeal carcinoma cell lines. Lab Invest 68: 716-727, 1993.
12. Collins SL, Weichselbaum RR, Dougherty M, Yokes EE and Stupp R: Head and Neck. In: Abeloff MD, Armitage JO, Lichter AS and Niederhuber JE (eds.) Churchill Livingstone Inc., New York, pp961-974, 1995.
13. Kozarsky KF and Wilson JM: Gene therapy: adenovirus vectors. Curr Opin Genet Dev 3: 499-503, 1993.
14. Liu T-J, Zhang W-W, Taylor DL, Roth JA, Goepfert H and dayman GL: Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 54: 3662-3667, 1994.
15. Zhang W-W, Fang X, Mazur W, French B A, Georges R and Roth JA: High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1: 5-13, 1994.
16. Clayman, GL, El-Naggar AK, Zhang W-W, Taylor DL, Roth JA, Goepfert H and Liu T-J: In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 55: 1-6, 1995.
17. Liu TJ, El-Naggar AK, McDonnell TJ, Steck KD, Wang M, Taylor DL and dayman GL: Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 55: 3117-3122, 1995.
18. Blagosklonny MV and El-Deiry WS: In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. Int J Cancer 67: 386-392, 1996.
19. WAF1/CIP1 deficient in PCNA interaction. Clin Cancer Res 2: 1221-1229, 1996.
20. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW and Vogelstein B: WAFI/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994.
21. WAF1/CIP1 expression. Nature Genet 15: 78-82, 1997.
22. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
23. WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 55: 2910-2919, 1995.
24. Min BM, Back JH, Shin KH, Gujuluva CN, Cherrick HM and Park NH: Inactivation of the p53 gene by either mutation or HPV infection is extremely frequent in human oral squamous cell carcinoma cell lines. Eur J Cancer 30B: 338-345, 1994.
25. Kim MS, Li SL, Bertolami CN, Cherrick HM and Park NH: State of p53, Rb and DCC tumor suppressor genes in human oral cancer cell lines. Anticancer Res 13: 1405-1413, 1993.